Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function
Open Access
- 23 January 2016
- journal article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 15 (5), 681-688
- https://doi.org/10.1016/j.jcf.2015.12.011
Abstract
No abstract availableKeywords
Funding Information
- NHLBI T32 (HL076118-08)
This publication has 42 references indexed in Scilit:
- Cystic fibrosisThe Lancet, 2009
- Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungsProceedings of the National Academy of Sciences of the United States of America, 2009
- RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in DiabetesJournal of the American Society of Nephrology, 2009
- Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in DiabetesDiabetes, 2008
- Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infectionCritical Care, 2007
- NCBI GEO: mining tens of millions of expression profiles--database and tools updateNucleic Acids Research, 2006
- Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cellsCell and tissue research, 2005
- Epidemiology of cystic fibrosis-related diabetesThe Journal of Pediatrics, 2005
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996